Environmental

COYA’s disclosed R&D intensity supports a relatively low direct environmental footprint versus manufacturing peers, but the benefit is limited by the company’s clinical-stage operating model.

The absence of debt reduces balance-sheet pressure that can force short-term cost cutting, yet it does not materially differentiate COYA from other small-cap biotech peers.

No material environmental controversies or emissions disclosures were provided, leaving COYA broadly neutral versus peers rather than clearly advantaged.

Compared with larger life-science companies, COYA likely has lower operational resource intensity, but the peer set’s generally modest environmental exposure keeps the relative edge limited.

Social

COYA’s high R&D spending relative to revenue indicates a science-driven model that can support patient-focused innovation, but it also reflects heavy dependence on clinical execution.

Very high stock-based compensation relative to revenue suggests stronger talent retention incentives than cash-constrained peers, though it can create dilution concerns for stakeholders.

No workforce, safety, or product-access disclosures were provided, so COYA cannot be credited for stronger social practices beyond its development-stage mission.

Against biotech peers, COYA appears broadly average on social factors because the sector’s main social risks center on trial conduct, access, and employee alignment.

Governance

Zero debt indicates limited creditor governance constraints, but it does not offset the governance burden associated with a highly dilutive capital structure.

Stock-based compensation at 391.8% of revenue signals materially weaker capital discipline than better-governed peers, because equity issuance can dominate stakeholder economics.

The very high net debt to EBITDA metric is not meaningful for a pre-commercial biotech profile, yet it still highlights limited earnings-based governance comparability.

No board, audit, or controversy data were provided, so COYA’s governance assessment remains anchored on compensation and capital structure signals.

Overall Score

COYA’s ESG profile is broadly middle-of-the-pack versus biotech peers, with modest operational advantages offset by weak capital-discipline signals.

Score Driver: Very High Stock-Based Compensation Relative To Revenue Weakens Governance Positioning Versus Peers.